Cancer immunotherapy: the beginning of the end of cancer?

BMC Medicine

Review

Ivan M. Blasutig¹  Sofia Farkona²  Eleftherios P. Diamandis³ 

[1] Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada;Department of Clinical Biochemistry, University Health Network, Toronto, ON, Canada;Clinical Biochemistry, Toronto General Hospital, 200 Elizabet St. Rm 3EB-365, M5G2C4, Toronto, ON, Canada;Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada;Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada;Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada;Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada;Department of Clinical Biochemistry, University Health Network, Toronto, ON, Canada;

关键词: Cancer;    Immunotherapy;    T cells;    Adoptive cellular therapy;    Cytotoxic T lymphocyte-associated protein 4;    Programmed cell death protein 1;    Immune checkpoint blockade;   

DOI  :  10.1186/s12916-016-0623-5

 received in 2016-01-28, accepted in 2016-04-29,  发布年份 2016

来源: Springer

【 摘 要 】

These are exciting times for cancer immunotherapy. After many years of disappointing results, the tide has finally changed and immunotherapy has become a clinically validated treatment for many cancers. Immunotherapeutic strategies include cancer vaccines, oncolytic viruses, adoptive transfer of ex vivo activated T and natural killer cells, and administration of antibodies or recombinant proteins that either costimulate cells or block the so-called immune checkpoint pathways. The recent success of several immunotherapeutic regimes, such as monoclonal antibody blocking of cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD1), has boosted the development of this treatment modality, with the consequence that new therapeutic targets and schemes which combine various immunological agents are now being described at a breathtaking pace. In this review, we outline some of the main strategies in cancer immunotherapy (cancer vaccines, adoptive cellular immunotherapy, immune checkpoint blockade, and oncolytic viruses) and discuss the progress in the synergistic design of immune-targeting combination therapies.

【 授权许可】

CC BY   
© Farkona et al. 2016